Primary Endpoint Met in the DETECT Endometriosis Imaging Study.
Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing 99mTc-maraciclatide, an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health announce that the primary endpoint has been met in the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) Phase II imaging study.
Dr Tatjana Gibbons from the team running the study at the Nuffield Department of Women’s and Reproductive Health at the University of Oxford, presented the headline data on the award stage at the World Congress on Endometriosis in Sydney. The trial has demonstrated a high correlation between locations of maraciclatide uptake identified on SPECT-CT and laparoscopy across all types of endometriotic lesions, including superficial peritoneal endometriosis, which is not well visualised with existing non-invasive imaging techniques.
The study is being led by Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford, together with Professor Krina Zondervan, Co-Director of the Endometriosis CaRe Centre and Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford.
Detailed results from the study will be made available later in the year.
Read the full story on the Nuffield Department of Women's & Reproductive Health website.